Windlas Biotech Limited

WINDLAS

INE0H5O01029

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:54 2024-05-31 EDT			5-day change	1st Jan Change
632.1 ^INR	+0.29%		+2.25%	+47.43%

05-20	Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
05-20	Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.

May 05, 2023 at 09:42 am

From January 1, 2023 to March 31, 2023, the company has repurchased 516,172 shares, representing 2.38% for INR 127.9 million. With this, the company has completed the repurchase of 867,747 shares, representing 3.99% for INR 217.97 million under the buyback announced on November 8, 2022.

Latest news about Windlas Biotech Limited

Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-20	CI
Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-20	CI
Windlas Biotech Commissions New Injectible Manufacturing Unit	04-02	MT
Windlas Biotech Limited Commissions Its Injectable Facility	04-02	CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Windlas Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23	23-09-12	CI
Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2022-23	23-08-18	CI
Windlas Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Windlas Biotech's Consolidated Profit Slips in Fiscal Q4	23-05-08	MT
Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-05	CI
Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-05	CI
Windlas Biotech Limited Recommends Dividend	23-05-05	CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.	23-05-05	CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.	23-05-03	CI
Windlas Biotech Limited's Equity Buyback announced on November 8, 2022 has closed with 867,747 shares, representing 3.98% for INR 217.97 million.	23-05-02	CI
Windlas Biotech's Consolidated Profit Climbs in Fiscal Q3	23-02-09	MT
Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer	23-02-09	CI
Windlas Biotech Appoints CEO	23-02-08	MT
Windlas Biotech Names New CEO	23-02-08	MT
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.	23-02-08	CI

Chart Windlas Biotech Limited

Duration

Period

More charts

Company Profile

Windlas Biotech Limited is an India-based company that is primarily engaged in the manufacturing and trading of pharmaceutical products. The Company provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Companyâs service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. It has capabilities for both solid and liquid pharmaceutical dosage forms. The Company markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. It also has a salesforce and distribution network spread across over 14 states. The Companyâs manufacturing facilities are located at Dehradun in Uttarakhand.

Sector

Pharmaceuticals

Calendar

2024-06-04 - Investor Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
WINDLAS BIOTECH LIMITED	+47.43%	158M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B